Business
Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists
ZTlido® is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists.1Total ZTlido® NRx (New Drug Prescription) market share for
About this update from Scilex Holding Company
[{"type":"text","content":"ZTlido® is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists.1Total ZTlido® NRx (New Drug Prescription) market share for the non-opioid branded pain treatment market grew to 14.2% in October 2023, compared to 11.8% in October 2022 according to prescription data from Symphony Health.1As previously reported certain preliminary unaudited financial results for gross sales for year-to-date through November 30, 2023. ZTlido® year-to-date gross sales through November 2023 were in the range of $125.0 million to $135.0 million, compared to $84.6 million for year-to-date through November 2022, representing growth in the range of approximately 48% to 60%. Projected full year gross sales for ZTlido® in 2023 are estimated to be in the range of $140.0 million to $150.0 million, compared to $96.0 million in 2022, representing estimated growth in the range of approximately 46% to 56%. PALO ALTO, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that according to prescription data from Symphony Health, ZTlido® is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists. Total ZTlido® NRx (New Drug Prescription) market share grew to 14.2% in October 2023, compared to 11.8% in October 2022 according to prescription data from Symphony Health. For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex participated in the type C meeting for purposes of pre-NDA dis...